<SEC-DOCUMENT>0001171843-20-002739.txt : 20200421
<SEC-HEADER>0001171843-20-002739.hdr.sgml : 20200421
<ACCEPTANCE-DATETIME>20200421161512
ACCESSION NUMBER:		0001171843-20-002739
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200417
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200421
DATE AS OF CHANGE:		20200421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NANOPHASE TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0000883107
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS PRIMARY METAL PRODUCTS [3390]
		IRS NUMBER:				363687863
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22333
		FILM NUMBER:		20805297

	BUSINESS ADDRESS:	
		STREET 1:		1319 MARQUETTE DRIVE
		CITY:			ROMEOVILLE
		STATE:			IL
		ZIP:			60446
		BUSINESS PHONE:		6303231200

	MAIL ADDRESS:	
		STREET 1:		1319 MARQUETTE DRIVE
		CITY:			ROMEOVILLE
		STATE:			IL
		ZIP:			60446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOPHASE TECHNOLOGIES CORPORATION
		DATE OF NAME CHANGE:	19970305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_042120.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title></title></head><body><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div></div><p style="text-align: center;"><font style="font-size: 14pt;"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong><br />_____________________</font></p><p style="text-transform: uppercase; text-align: center;"><font style="font-size: 14pt;"><strong>Form 8-K</strong><br />_____________________</font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>CURRENT REPORT</strong></font></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></font></p><p align="center"><font style="font-size: 10pt;">Date of Report (Date of earliest event Reported): <!--April 21, 2020-->April 17, 2020 &#160;</font></p><p align="center"><font style="font-size: 12pt;"><strong>NANOPHASE TECHNOLOGIES CORPORATION </strong></font><br /><font style="font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;"><strong>Delaware</strong></font></td><td align="center" width="34%"><font style="font-size: 10pt;"><strong>0-22333</strong></font></td><td align="center" width="33%"><font style="font-size: 10pt;"><strong>36-3687863</strong></font></td></tr><tr valign="top"><td align="center" width="33%"><font style="font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</font></td><td align="center" width="34%"><font style="font-size: 10pt;">(Commission File Number)</font></td><td align="center" width="33%"><font style="font-size: 10pt;">(I.R.S. Employer Identification Number)</font></td></tr></table><p><font style="font-size: 10pt;">&#160;</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="bottom"><td align="center" width="50%"><font style="font-size: 10pt;"><strong>1319 Marquette Drive, Romeoville, Illinois  60446</strong><!--UNITED STATES --></font></td></tr><tr valign="top"><td align="center" width="50%"><font style="font-size: 10pt;">(Address of Principal Executive Offices) (Zip Code)</font></td></tr></table><p align="center"><font style="font-size: 10pt;"><strong>(630) 771-6700 </strong><br />(Registrant's telephone number, including area code)</font></p><p align="center"><font style="font-size: 10pt;"><strong>Not applicable</strong><br />(Former name or former address, if changed since last report)</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td colspan="3"><font style="font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br /><br /></font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr valign="top"><td width="21"><font style="font-size: 10pt;">&#160;</font></td><td width="40"><font style="font-size: 10pt;">[ &#160; ]</font></td><td nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&sect;240.12b-2).&#160;Emerging growth company [&#160;&#160; ]</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><p style="font-size: 10pt; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160; ]</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size: 10pt; margin: 0pt;">&#160;</p><table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 40%; border: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Title of each class</font></td><td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Trading Symbol(s)</font></td><td style="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Name of each exchange on which registered</font></td></tr><tr style="vertical-align: top;"><td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Common Stock</font></td><td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">NANX</font></td><td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">OTCQB</font></td></tr></table><div style="margin-top: 12pt; margin-bottom: 3pt;"><div style="font-size: 1pt; border-top: Black 1.1pt solid; border-bottom: Black 2.5pt solid; width: 100%;"><font style="font-size: 10pt;">&#160;</font></div>&#160;</div><hr style="page-break-after: always;" noshade="noshade" /><p><font style="font-size: 10pt;">  <strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 1.01. Entry into a Material Definitive Agreement.</strong></font></p><p><font style="font-size: 10pt;">
 <p>On April 17, 2020, Nanophase Technologies Corporation (together with its subsidiary, the &#8220;Company&#8221;) entered into a promissory note, dated as of April 16, 2020 (the &#8220;Note&#8221;) in favor of Libertyville Bank and Trust Company, N.A. (the &#8220;Lender&#8221;) evidencing a loan in the aggregate principal amount of $951,600 (the &#8220;Loan&#8221;) pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), which was enacted on March 27, 2020.<br /> <br /><em>Interest Rate</em><br /> <br />The interest rate on the Loan is 1.00% per year.<br /> <br /><em>Maturity</em><br /> <br />The term of the Loan is two years. The Company will be required to pay any unforgiven principle and interest in eighteen equal monthly installments, with the first payment being due on November 17, 2020 and continuing on the same day of each subsequent month until the date of maturity. The Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties.<br /> <br /><em>Potential Loan Forgiveness</em><br /> <br />Under the PPP, the Company may apply for forgiveness of the amount due on the Loan in an amount equal to the sum of the following costs incurred during the 8-week period beginning on the date of the first disbursement of the Loan: (a) payroll costs, (b) any payment of interest on a covered obligation (which shall not include any prepayment of or payment of principal on a covered mortgage obligation), (c) any payment on a covered rent obligation, and (d) any covered utility payment, calculated in accordance with the terms of the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the Loan in whole or in part.<br /> <br /><em>Events of Default</em><br /> <br />The Loan provides for customary events of default, including payment defaults, cross-defaults on any other loan with the lender, and breaches of the terms of the Note. The Loan may be accelerated upon the occurrence of an event of default, among other remedies available to the Lender.<br /> <br />The foregoing description of the Loan is a summary of, and does not purport to be a complete statement of, the terms of the Note or the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the full text of the Note, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) as an exhibit to the Company&#8217;s next quarterly report under the Securities Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p> </font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</strong></font></p><p><font style="font-size: 10pt;">
 <p>The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.</p> </font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 7.01. Regulation FD Disclosure.</strong></font></p><p><font style="font-size: 10pt;">
 <p>On April 21, 2020, the Company issued a press release announcing the receipt of the Loan.&#160; A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.</p>   <p>The information, including the exhibit hereto, furnished in this Item 7.01 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange</p> </font></p><p><font style="font-size: 10pt;"><strong>  </strong></font></p><p><font style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></font></p><p><font style="font-size: 10pt;">
 <p>(d) Exhibits.</p>  <table style="border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><u>Exhibit No.</u></font></td><td class="hugin"><font style="font-size:10pt;">&#160; &#160; &#160; &#160; &#160;</font></td><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><u>Description</u></font></td></tr><tr><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></font></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">Press Release dated April 21, 2020</a></font></font> </font></td></tr></table>  <p><strong>Forward-Looking Statements</strong></p>   <p>This Current Report on Form 8-K contains various forward-looking statements within the meaning of&#160;Section&#160;27A of the Securities Act of 1933, as amended, Section&#160;21E of the Exchange Act, and the Private Securities Litigation Reform Act, as amended.&#160;Forward-looking statements include those containing such words as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecasts,&#8221; &#8220;hopes,&#8221; &#8220;outlook,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;targets,&#8221; &#8220;will,&#8221; &#8220;will likely result,&#8221; &#8220;would,&#8221; or other words of similar meaning. All statements that reflect the Company&#8217;s expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding potential uses of the proceeds of the Loan, potential forgiveness of the Loan, and statements about the Company&#8217;s strategies, objectives, goals, targets, outlook, and business and financial prospects. Forward-looking statements are subject to a number of known and unknown risks, uncertainties and other factors and are not guarantees of future performance. Actual results, performance or outcomes may differ materially from those expressed in or implied by those forward-looking statements. Important factors that could cause the Company&#8217;s actual results to differ materially from those expressed or implied in the forward-looking statements include: (a)&#160;concerns with or threats of, or the consequences of, pandemics, contagious diseases or health epidemics, including the coronavirus pandemic; and (b)&#160;the other risk factors disclosed in the Company&#8217;s other reports filed with the Commission. The Company disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events or otherwise, except as required by applicable law.</p> </font></p><p><font style="font-size: 10pt;"></font></p><p><font style="font-size: 10pt;"></font></p><hr style="page-break-after: always;" noshade="noshade" /><p align="center"><font style="font-size: 10pt;"><strong>SIGNATURE</strong></font></p><p><font style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr valign="top"><td valign="top" width="49%"><font style="font-size: 10pt;">&#160;</font></td><td style="font-size: 12pt;" colspan="2" valign="top"><font style="font-size: 10pt;"><strong>NANOPHASE TECHNOLOGIES CORPORATION </strong></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">Date: April 21, 2020</font></td><td width="2%"><font style="font-size: 10pt;">By:&#160;</font></td><td style="text-decoration: underline;" width="49%"><font style="font-size: 10pt;">/s/ Jess Jankowski&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Jess Jankowski</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;">Chief Executive Officer</font></td></tr><tr valign="top"><td width="49%"><font style="font-size: 10pt;">&#160;</font></td><td width="2%"><font style="font-size: 10pt;">&#160;</font></td><td width="49%"><font style="font-size: 10pt;"></font></td></tr></table><p /></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Nanophase Receives Funding Under Paycheck Protection Program</strong></font></p><p style="text-align: center;"><strong></strong></p><p ></p>
 <p align="justify">ROMEOVILLE, Ill., April  21, 2020  (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported that it received funding in the form of a loan under the Paycheck Protection Program (the &#8220;PPP&#8221;),&#160;under Division A, Title I of&#160;Coronavirus Aid, Relief, and Economic Security Act&#160;(&#8220;CARES Act&#8221;), which was enacted on March 27, 2020.<br ></p>  <p align="justify">&#8220;We are happy to announce that our request for funding under the PPP was granted, being funded on April 17, 2020. The amount of the loan was $0.95 million. We believe that we will incur costs over the next eight weeks amounting to at least 80% of the loan balance, which we expect to be forgiven under the terms of the PPP,&#8221; stated Jess Jankowski, President and CEO. &#8220;We plan on continuing operations, taking necessary precautions to protect our employees, their families, and our community during this disruption, as we manufacture products and ingredients within sectors that are part of our nation&#8217;s critical infrastructure. We are both honored and proud to be contributing to our national public health, economic security, and safety through the materials we make for use in medical diagnostics.&#8221;&#160;</p>  <p align="justify">&#8220;We are working to complete our quarterly review prior to release of our Q12020 financial results, which we plan to make available in early May. As I mentioned in our most recent financial release, we have visibility through Q22020, and now through July. We don&#8217;t expect to have better visibility for the second half of 2020 until late May or early June,&#8221; added Jankowski.&#160;</p>  <p align="justify">&#8220;Our top priorities remain our people and their families, our neighbors, our customers, and contributing in any way that we can to help our nation in these difficult circumstances.&#8221; &#160;</p>  <p align="justify"><strong><u>About Nanophase Technologies</u></strong><br >Nanophase Technologies Corporation (NANX), <u>www.nanophase.com</u>, is a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, as well as providing solutions for industrial product applications. Using a platform of patented and proprietary integrated technologies, the Company creates products with unique performance attributes from two ISO 9001 and ISO 14001 registered facilities. Nanophase delivers commercial quantity and quality engineered materials both as ingredients, and as part of fully formulated products, in a variety of formats.&#160;</p>  <p align="justify"><strong><u>Forward-Looking Statements</u></strong><br ><em>This press release contains words such as &#8220;expects,&#8221;&#8221; shall,&#8221; &#8220;will,&#8221; &#8220;believes,&#8221; and similar expressions that are intended to identify forward-looking statements</em><em> within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company&#8217;s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company&#8217;s results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company&#8217;s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company&#8217;s nanocrystalline materials; the Company&#8217;s manufacturing capacity and product mix flexibility in light of customer demand; the Company&#8217;s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company&#8217;s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company&#8217;s Form 10-K filed March 30, 2020. In addition, the Company&#8217;s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingen</em><em>cies.</em></p>  <p align="justify">COMPANY CONTACT<br >Investor Relations<br >630-771-6705</p>  <p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
